Eribulin[2]
Overview
Eribulin is a synthetic analog of halichondrin B, a natural product derived from marine sponges. Developed by Eisai Co., it received FDA approval in 2010 for metastatic breast cancer and later for liposarcoma. Its mechanism involves binding to tubulin, disrupting microtubule dynamics, and inducing mitotic arrest. As a non-taxane inhibitor, eribulin exhibits distinct binding properties, making it effective in taxane-resistant cases. It is administered intravenously and is classified as a cytotoxic antineoplastic agent. Clinical trials demonstrated improved overall survival in refractory patients, solidifying its role in oncology.
Physical and Chemical Properties
Eribulin mesylate is a white crystalline powder with a molecular weight of 729.91 g/mol. It is hygroscopic and degrades at temperatures above 185°C. The compound is soluble in aqueous solutions and polar organic solvents, facilitating formulation for intravenous use. Its macrocyclic structure includes multiple ether and ketone functional groups, contributing to its high affinity for tubulin. Stability studies recommend pH-controlled solutions (4-6) and protection from light to prevent degradation. Analytical methods like HPLC are employed for purity verification in pharmaceutical preparations.
Main Applications
Eribulin is primarily used to treat metastatic breast cancer in patients who have failed at least two prior chemotherapy regimens. It is also approved for advanced liposarcoma when other therapies are ineffective. Off-label uses are being explored in ovarian and bladder cancers. Clinical efficacy stems from its ability to inhibit microtubule growth without affecting shortening, leading to irreversible mitotic blockade. Compared to other microtubule-targeting drugs, eribulin shows a lower incidence of neuropathy but requires monitoring for hematologic toxicity, particularly neutropenia.
Safety and Storage
As a cytotoxic agent, eribulin requires strict handling protocols. Healthcare personnel must use gloves, gowns, and eye protection during preparation. Accidental exposure necessitates immediate decontamination. The drug is classified as a hazardous substance under OSHA guidelines. Unopened vials should be stored refrigerated (2-8°C) and protected from light. Reconstituted solutions are stable for up to 24 hours at room temperature or 48 hours refrigerated. Compatibility studies indicate it should not be mixed with other drugs in the same infusion line due to precipitation risks.
B2B Procurement Guide
Pharmaceutical purchasers should prioritize suppliers with WHO-GMP or FDA-approved manufacturing facilities. Batch-specific certificates of analysis (CoA) must confirm purity ≥98% and endotoxin levels <5 EU/mg. Cold chain logistics are critical; verify temperature monitoring during transit. Bulk procurement contracts often include clinical support services, such as adverse event reporting systems. Pricing is tiered based on volume, with academic medical centers typically receiving discounted rates. Lead times average 4-6 weeks; maintain buffer stock to avoid treatment delays.